Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
October 23, 2024 09:15 ET
|
Cyclacel
NEW CLINICAL DATA FROM ONGOING, PHASE 2 STUDY OF ORAL FADRACICLIB AT THE 2024 ENA SYMPOSIUM.
Patients preselected for CDKN2A and/or CDKN2B abnormalities
Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
June 03, 2024 08:00 ET
|
Cyclacel
CYCLACEL PHARMACEUTICALS REPORTS NEW CLINICAL DATA AT 2024 ASCO ANNUAL MEETING HIGHLIGHTING ORAL FADRACICLIB’S POTENTIAL AS A PRECISION MEDICINE FOR CANCER
The Sovini Group continues their Data Journey with Simpson Associates as their Fabric Partner
May 02, 2024 08:30 ET
|
Simpson Associates
Simpson Associates announces a partnership with The Sovini Group to implement Microsoft’s Fabric Platform, starting with our Proof of Concept.
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 19, 2024 16:05 ET
|
Cyclacel
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support...
Assosia and Simpson Associates Team Up to Unlock Product Matching Potential with Machine Learning
February 08, 2024 04:57 ET
|
Simpson Associates
Read our Press Release on how Simpson Associates have teamed up with Assosia to precisely product match using Machine Learning.
Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study
December 15, 2022 06:59 ET
|
Synlogic, Inc.
Results include -38% reduction in urinary oxalate compared to placebo in Roux-en-Y gastric bypass patients Favorable safety and tolerability, with frequency and severity of adverse events similar...
Medaro Spodumene Processing Technology Produces High-Purity Lithium Carbonate
February 10, 2022 07:00 ET
|
Medaro Mining Corp.
—Readily formed Li2CO3 is 99.91% pure VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Medaro Mining Corp. (CSE: MEDA) (OTC: MEDAF) (FWB: 1ZY) (“Medaro” or the “Company”), a...
Medaro Hard Rock Lithium Extraction Process Achieves Proof of Concept
January 13, 2022 07:00 ET
|
Medaro Mining Corp.
VANCOUVER, British Columbia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Medaro Mining Corp. (CSE: MEDA) (OTC: MEDAF) (FWB: 1ZY) (“Medaro” or the “Company”), a multi-faceted mineral explorer and joint venture...
ViGeneron signs global collaboration agreement for ophthalmic gene therapy development
January 05, 2021 02:00 ET
|
ViGeneron GmbH
Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional targetThe companies will use ViGeneron’s proprietary vgAAV...
Standard Lithium Successfully Completes Proof-of-Concept of Modern Lithium Extraction and Crystallisation Technology and Makes Better Than Battery Quality Lithium Carbonate
December 03, 2020 08:00 ET
|
Standard Lithium
HIGHLIGHTS >99.9% purity lithium carbonate produced (aka ‘3 nines’)Successful proof-of-concept of modern lithium processing technologyStart-to-finish direct extraction of lithium from brine in...